Did you find this information helpful?
TAURITMO 25MG CAPSULE
Salt Composition : Midostaurin
Manufacturer : NOVARTIS INDIA LTD
Origin of Medicine : Switzerland
4 Capsule(s) In A Strip
PAP Information : Contact us for latest updates.
Patient Assistance Programs
Introduction to Tauritmo 25mg Capsule
Tauritoma 25mg capsule contains the active substance midostaurin. It is an anti-cancer medicine that belongs to the class of medications called tyrosine kinase inhibitors. It is combined with other chemotherapy medications to treat acute myeloid leukemia (AML) in adults with a defect in a gene called FLT3. Acute myeloid leukemia is a form of cancer that starts in certain WBC called myeloid cells in which the body overproduces these cells abnormally. The medicine is also used in adults to treat aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Do not take Tauritoma 25mg capsule if you are allergic to Midostaurin or any other ingredients of this medicine. Inform your healthcare professional if you have any symptoms of an infection, heart disorder, lung problems, or problems with breathing. If you experience any of these symptoms, such as fever, sore throat, mouth ulcers, cough with or without mucous, chest pain, difficulty breathing, or swelling in the body parts after taking the medicine, immediately report it to your doctor.
This medicine is not recommended for children and adolescents below 18 years of age. Inform your physician if you are pregnant, breastfeeding, or planning for pregnancy before initiating the therapy. Tauritoma 25mg capsule may reduce fertility in men and women; discuss this with your doctor before starting the therapy. This medicine's most common side effects are fever with reduced blood cell counts, nausea, vomiting, headache, musculoskeletal pain, increased blood glucose levels, and respiratory tract infection.
Uses of Tauritmo 25mg Capsule
- Acute myeloid leukemia (AML)
- Aggressive systemic mastocytosis (ASM)
- Systemic mastocytosis with associated hematological neoplasm (SM-AHN)
- Mast cell leukemia (MCL)
Therapeutic Effects of Tauritmo 25mg Capsule
Tauritoma 25mg capsule is a kinase inhibitor that potently inhibits multiple receptor tyrosine kinases. It blocks the action of the kinases in the abnormal cells that express FLT3 mutant genes and stops their division and growth.
Interaction of Tauritmo 25mg Capsule with other drugs
Inform your healthcare provider about all the medicines you are taking, including prescription medications, over-the-counter medications, vaccinations, nutritional and vitamin supplements, and herbal products. Certain medications may interact with the effects of Tauritoma 25mg capsule and reduce its effectiveness by causing undesirable side effects.
More Information about Tauritmo 25mg Capsule
- Store Tauritoma 25mg capsule at room temperature (25°C)
- keep the capsule away from the reach of children and pets.
- If you miss a dosage, take it as soon as you remember. If it is almost time for the next dose, skip the missing dose.
- Do not take a double dose to compensate for a missed dose.
How to consume Tauritmo 25mg Capsule
Your doctor will decide the dose and duration of the treatment based on your disease condition, severity, and other factors. Take the Tauritoma 25mg capsule as prescribed by your doctor. Do not open, break, crush, or chew the capsules. Swallow the capsule whole with a glass of water. Take the capsules with food at the same time each day.
Safety Advices for Tauritmo 25mg Capsule
Tauritoma 25mg capsule is unsafe to administer in pregnant women because it may cause birth defects. Inform your physician if you are pregnant, suspect pregnancy, or planning to become pregnant. Using effective contraception during the treatment and for at least 4 months after your last dose is necessary.
Breastfeeding is not recommended in patients taking Tauritoma 25mg capsule because the medicine passes into the breast milk in small amounts and may harm the baby.
It is unknown whether Tauritoma 25mg capsule can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
Tauritoma 25mg capsule should be cautiously administered in patients with severe liver diseases. Dose adjustments are necessary for severe liver failure. Inform your physician if you have liver problems before initiating the therapy.
It is unsafe to consume alcohol when taking Tauritoma 25mg capsule because it may cause alcohol-related problems, epilepsy, or liver problems.
Driving vehicles or operating machinery after taking Tauritoma 25mg capsule is unsafe as you may develop dizziness and vertigo.
Side Effects of Tauritmo 25mg Capsule
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
- Swelling in the lower limbs
- Skin rash
- Increased blood sugar levels
- Abdominal pain
- Constipation, diarrhea
- Nausea, vomiting
- Musculoskeletal pain
- Bleeding from nose
- Upper respiratory infection
- Heart failure
- GI bleeding
- Fever with decreased blood cell counts
- Hypersensitivity reactions
- Kidney problems
- Blood infection
Word of Advice
Do not breastfeed during the treatment with Tauritoma 25mg capsule and for at least 4 months after the last dose. Avoid grapefruit juice during the treatment with this medicine. If you vomit after taking this medicine, do not take another capsule to make up the dose. If you are a male patient with a female partner with reproducing potential, use effective contraception during the treatment and for 4 months after the last dose. Your doctor will perform regular blood tests during the treatment to monitor the number of blood cells and electrolytes in your body. Your heart and lung function will also be checked regularly. This medicine may make you bleed, bruise, or get infections more easily. Take precautions to prevent illness and injury.
Q 1. What are the cautions of Tauritoma 25mg capsule?
Tell your doctor immediately if you start to have swelling of your face, lower limbs or skin, fever, sore throat, mouth ulcers, cough with or without mucous, chest pain or discomfort, trouble breathing, shortness of breath, light-headedness, fainting, dizziness, blue discoloration of your lips, hands or feet.
Q 2. Can Tauritoma 25mg capsule cause vomiting?
Yes, Tauritoma 25mg capsule has a moderate emetic effect and can cause vomiting. Do not take an extra capsule if you have vomited after taking your first dose.
Q 3. Does Tauritoma 25mg capsule cause hair loss?
No, hair loss is not a side effect of Tauritoma 25mg capsule. Hair loss can happen due to cancer itself. Consult your doctor if you have excessive hair loss.
Q 4. How will I be monitored during the treatment with Tauritoma 25mg capsule?
Your doctor will perform regular blood tests during treatment with Rydapt in order to monitor the number of blood cells (white blood cells, red blood cells, and platelets) and electrolytes such as calcium, potassium, and magnesium in your body. Your heart and lung function will also be checked regularly.
Q 5. How long does it take Tauritoma 25mg capsule to work?
Tauritoma 25mg capsule is a long-term treatment. Most people who benefit from this treatment will notice an improvement in the first 12 weeks of starting treatment.
Q 6. What will happen if I stop taking Tauritoma 25mg capsule suddenly?
Stopping your treatment suddenly may cause your condition to become worse. Do not stop taking your medicine without consulting your doctor.
Fact Box of Tauritmo 25mg Capsule
Molecule name: Midostaurin
Therapeutic class: Antineoplastics
Pharmacological class: Tyrosine kinase inhibitor
1. Acute myeloid leukemia (AML)
2. Aggressive systemic mastocytosis (ASM)
3. Systemic mastocytosis with associated hematological neoplasm (SM-AHN)
4. Mast cell leukemia (MCL)
- Rydapt 25 mg soft capsules - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk. [revised on 2022] [cited 2023 Apr 13]. Available from: https://www.medicines.org.uk/emc/product/9134/smpc
- Highlights Of Prescribing Information - Midostaurin, [revised on 2017] [cited 2023 Apr 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
- Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236.
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.
100% secure and trusted payment protection
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.